Sun Pharmaceutical Industries is currently trading at Rs. 844.05, up by 9.85 points or 1.18% from its previous closing of Rs. 834.20 on the BSE.
The scrip opened at Rs. 836.30 and has touched a high and low of Rs. 844.05 and Rs. 833.25 respectively. So far 60588 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 877.40 on 03-Sep-2014 and a 52 week low of Rs. 552.50 on 14-Mar-2014.
Last one week high and low of the scrip stood at Rs. 844.05 and Rs. 748.15 respectively. The current market cap of the company is Rs. 172942.19 crore.
The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.05% and 8.29% respectively.
Team of US FDA (Food and Drug Administration) inspectors, which recently conducted a surprise audit on a Gujarat unit of Sun Pharmaceutical Industries, has reportedly submitted Form 483. Submission of Form 483 means the FDA team found certain procedural issues with respect to the plant's running and seeks corrective action but may not imply an immediate import ban.
The FDA team has made 23 observations (four for injectable units, four for oral solid unit and rest for the quality-control lab) at the Halol unit in Gujarat, which accounts for about 25 percent of Sun’s US sales. The US market accounts for 60 percent of the company’s total sales. Though, the FDA did not find any data integrity issues with the plant.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: